Clywedog reports final Phase Ib trial results for balomenib

Phase 1positivebalomenibPositive

AI Analysis

Summary

Clywedog Therapeutics reported positive final Phase Ib results for balomenib, an oral investigational drug for type 2 diabetes, demonstrating reductions in HbA1c and fasting plasma glucose that were maintained after treatment cessation.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Reductions in HbA1c and fasting plasma glucose maintained after treatment ended

Importance:5/10

Sentiment:

0.70

Phase Ibdiabetesoral drugclinical trial results

Related Companies

$GLUC $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 25, 2026 8:22 AM

Read Original